subsequent stem cell harvest, both preceded by rituximab 375 mg/m2 infusion 3 etoposide 2.4 g/m2 plus cisplatin 100 mg/m2 plus stem cell rescue 3 high-dose BCNU, etoposide, cytosine arabinoside, and melphalan (HD-BEAM) plus stem cell rescue. Two additional weekly doses of rituximab, 375 mg/m2, ended the treatment. Stem cells harvested after chemotherapy with cytosine arabinoside plus rituximab were negative for lymphoma cell contamination (as assessed by polymerase chain reaction [PCR] using a patient's specific primer) and were used to support the final myeloablative BEAM regimen. The patient achieved a complete clinical and molecular remission. The treatment was well tolerated, and the patient was discharged in good clinical conditions. Consolidation radiotherapy (30 Gy) on sacral region was given on an outpatient setting. On day ϩ20 from the end of treatment, the patient developed an asymptomatic CMV infection, documented by a positive pp65 assay (3 and 4 positive nuclei/200 000 cells), and was treated with gancyclovir in our outpatient department until negativization of the assay in 2 consecutive controls. Seven months later, the patient presented with progressive pulmonary and bone disease, confirmed by computed tomography (CT)-scan as well as by histological and immunophenotypic analysis of the pulmonary localizations. At that time, complete serological tests were repeated, confirming the presence of HCV-RNA. The patient was treated with vinorelbine (25 mg/m2) in association with rituximab, 375 mg/m2, for 7 overall courses, achieving a partial response. In February 2002, soon after the end of the last dose of rituximab, the patient experienced mental status changes and ataxia. A brain CT scan revealed multiple hypodense lesions, while magnetic resonance imaging (MRI) showed areas of white matter disease consistent with a demyelinating process. A cerebrospinal fluid examination was positive for BK papovavirus DNA. Despite treatment with cidofovir, the patient died in April 2002.
The present report adds to the list of unusual viral infections in patients treated with high-dose chemotherapy and rituximab. Of note, the BK papovavirus isolated here causes leukoencephalopathy with 10-fold less frequency 3 compared with the JC papovavirus responsible for the 2 cases of progressive multifocal leukoencephalopathy reported by Goldberg et al. 1 The contributory role of rituximab, if any, is only tentative and far from being proved. 4, 5 However, this additional case further strengthens the need for an accurate surveillance and reporting of rare viral infections that might occur in heavily pretreated lymphoma patients receiving peritransplantation rituximab. To the editor:
Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells
Branford and colleagues have reported on the development of resistance to imatinib mesylate in patients with chronic myeloid leukemia (CML) and with Ph ϩ acute lymphoblastic leukemia (ALL) treated with this drug. Their report highlights the biologic interest of this phenomenon, which, at the same time, is cause for considerable concern from the clinical point of view. These and other previous studies [2] [3] [4] [5] [6] [7] demonstrate that there are various mechanisms of resistance to imatinib. In a substantial proportion of patients, the basis for resistance is a genetic change in the BCR-ABL gene itself: particularly, point mutations within the protein tyrosine kinase (PTK) domain. This genetic mechanism has 2 interesting implications. First, it must be highly specific for imatinib; there is no reason to expect that there would be cross-resistance with any other commonly used chemotherapeutic agent. Everything leads one to believe that clinical resistance to imatinib, just like antibiotic resistance in bacteria, arises through a process whereby the drug itself selects for rare pre-existing mutant cells, which gradually outgrow drug-sensitive cells. Although this will require a very high sensitivity, it should be possible to find ways to detect such rare mutant cells in pretreatment samples.
Second, as we all share the excitement of imatinib being the herald of a new generation of antitumor agents, [8] [9] [10] we may still have to learn some of the implications. "Conventional" cytotoxic agents target fundamental processes within the cell, such as DNA replication or the mitotic spindle. In principle, certain mutations in any of the genes involved in one such process could confer resistance toward a cytotoxic agent that is directed against that process. But since the genes involved in, say, DNA replication are indispensable in every cell, there may be enormous constraints for a mutation in any of them to yield a cell that is drug-resistant and viable at the same time. By contrast, since the inhibition of the normal Abl PTK by imatinib has relatively few side effects, it must mean that its function is dispensable in most cells, including normal granulocytes: therefore, there may be less stringent constraints for a mutation in the ABL gene to produce a PTK that is no longer inhibited by imatinib in a cell that is viable. The same reasoning may be extended to other genes that are involved in this or in any other of the multiple signal-transduction pathways known to exist in various types of cells and that, when mutated in tumors, are attractive targets for new drugs 11, 12 Thus a relatively high frequency of resistance mutations may be a price to pay for the target specificity and consequent reduced toxicity of new chemotherapeutic agents.
Is this going to be a major deterrent to the use of these drugs, or even to their development? Of course we hope not. Indeed, it is conceivable that new analogs can be synthesized that will break through the most common mutations conferring resistance to imatinib. But more in general, we can perhaps apply the principles learned from infectious diseases, where the use of a drug combination has been a time-honored approach aiming to minimize the risk of antibiotic resistance, since the statistical probability of a single bacterial cell having 2 rare mutations must be very low. There is every reason to assume that the same principles apply to mammalian somatic cells. One wonders whether, in a not too distant future, initial therapy of CML with imatinib alone will be frowned upon, just like single antibiotic therapy for tuberculosis would be frowned upon today. It seems not impossible that, just as "triple" or "quadruple" therapy is the standard of care today for infections by M tuberculosis, a 2-drug approach 13 (perhaps cytosine-arabinoside or even the old busulphan together with imatinib) might become the standard of care for newly diagnosed CML. 
